Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations

Next Previous
X
Search
Trial Profile

A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bleximenib (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Fludarabine (Primary) ; Pegaspargase (Primary) ; Vincristine (Primary) ; Antineoplastics
  • Indications Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 22 Aug 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 22 May 2024 Planned initiation date changed from 29 May 2024 to 26 Dec 2025.
    • 05 Dec 2023 Planned End Date changed from 11 Sep 2026 to 29 Jan 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top